The Pulmonary Fibrosis Basis (PFF) introduced Franck Rahaghi, MD, MHS, FCCP, as its incoming president, CEO, and chief medical officer, efficient Sept 15.
Following an intensive search, Rahaghi was chosen primarily based on his long-time dedication to care, analysis, and schooling in interstitial lung illness and pulmonary fibrosis, in line with a launch from the PFF.
Rahaghi’s in depth experience in interstitial lung illness led him to his newest position as director of the interstitial lung illness program on the Cleveland Clinic Florida, a member of the PFF Care Middle Community (CCN). In 2003, he joined the medical heart as employees attending in pulmonary crucial care and director of the pulmonary hypertension clinic. He grew to become chairman of the division of pulmonary and significant care in 2015 and can proceed his tutorial involvement on the Cleveland Clinic Florida.
“I’m excited to steer the Pulmonary Fibrosis Basis. I consider I’ve been making ready for this my complete life,” says Rahaghi in a launch. “I sit up for working with the PFF board, employees, and your entire group to create a world the place these devastating illnesses not exist.”
Over the previous 15 years, Rahaghi has been concerned with a number of medical trials for pulmonary fibrosis and pulmonary hypertension. Rahaghi has authored 48 peer-reviewed publications and has revealed 49 abstracts. He’s a medical professor of medication on the Cleveland Clinic Lerner Faculty of Drugs.
“Franck Rahaghi is an distinctive pulmonologist and researcher who has led our care heart website on the Cleveland Clinic Florida and has partnered with the CCN on a number of initiatives,” says David McNinch, chairman of the PFF board of administrators, in a launch. “He brings a depth of expertise working with key stakeholders of business, authorities, and academia with a sole focus of bettering affected person outcomes. We consider that Franck’s talent set will assist us make nice strides towards our targets of optimum affected person care and fast growth of recent therapies for interstitial lung illness.”
Rahaghi is board-certified in pulmonary medication and significant care medication. He’s a graduate of the College of California at San Diego (BS in biomedical engineering), the College of California at Berkeley (MHS in well being coverage and finance), and the College of California at San Francisco (physician of medication diploma).
He accomplished his coaching in inner medication on the College of Minnesota and the College of Illinois at Chicago. Rahaghi did his fellowship in pulmonary and significant care at Weill Cornell Medical Middle in New York. He’s a member of the American Thoracic Society, American Faculty of Chest Physicians, Pulmonary Hypertension Affiliation, and a number of other different skilled organizations.
Rahaghi succeeds Invoice Schmidt, former president and CEO of the PFF, and Dr Joseph Lasky, the muse’s former chief medical officer. Schmidt and Lasky will proceed to serve the PFF as consultants.
Picture caption: Franck Rahaghi, MD, MHS, FCCP
Picture credit score: Pulmonary Fibrosis Basis / PR Newswire
